Precigen Inc. (PGEN)
NASDAQ: PGEN
· Real-Time Price · USD
1.34
-0.05 (-3.94%)
At close: May 07, 2025, 3:59 PM
1.34
0.00%
After-hours: May 07, 2025, 05:03 PM EDT
-3.94% (1D)
| Bid | 1.31 |
| Market Cap | 395.52M |
| Revenue (ttm) | 3.92M |
| Net Income (ttm) | -126.23M |
| EPS (ttm) | -0.47 |
| PE Ratio (ttm) | -2.85 |
| Forward PE | 46.5 |
| Analyst | Buy |
| Ask | 1.37 |
| Volume | 897,687 |
| Avg. Volume (20D) | 1,586,161 |
| Open | 1.41 |
| Previous Close | 1.40 |
| Day's Range | 1.34 - 1.44 |
| 52-Week Range | 0.65 - 2.17 |
| Beta | 1.82 |
About PGEN
undefined
Industry n/a
Sector n/a
IPO Date n/a
Employees NaN
Stock Exchange n/a
Ticker Symbol PGEN
Website n/a
Analyst Forecast
According to 0 analyst ratings, the average rating for PGEN stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.
Stock ForecastsNext Earnings Release
Precigen Inc. is scheduled to release its earnings on May 20, 2025,
during market hours.
Analysts project revenue of ... Unlock content with Pro Subscription
Analysts project revenue of ... Unlock content with Pro Subscription
3 months ago
+18.58%
Precigen shares are trading higher after HC Wainwr...
Unlock content with
Pro Subscription
4 months ago
+28.47%
Precigen shares are trading higher after the company announced it's seeking FDA priority review for its gene therapy targeting rare respiratory disease.
2 months ago · seekingalpha.com
Precigen: UltraCAR-T Development Brings Another Side Of Pipeline AdvancementBLA of PRGN-2012 for patients with Recurrent Respiratory Papillomatosis was accepted by FDA with a Priority Review date of August 27th of 2025. Marketing approval of PRGN-2012 for RRP would be huge be...
